Response rate with weekly epirubicin and docetaxel as neoadjuvant chemotherapy (NAC) for locally-advanced breast cancer (BC).

被引：0
|
作者：
Chen, SC
Chang, HK
Lin, YC
Leung, WM
Chang, JT
Cheung, YC
Hsueh, S
Lo, YF
Tsai, HP
Chen, MF
机构：
[1] Chang Gung Mem Hosp, Taipei 10591, Taiwan
[2] Breast Canc Study Grp, Taipei 10591, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：99S / 99S
页数：1
相关论文
共 50 条
  • [1] The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer
    Hirano, A
    Shimizu, T
    Imamura, H
    Watanabe, O
    Kinoshita, J
    Okabe, T
    Kimura, K
    Kamimura, M
    Domoto, K
    Aiba, M
    Ogawa, K
    [J]. ANTICANCER RESEARCH, 2006, 26 (1B) : 581 - 584
  • [2] Docetaxel and epirubicin as neoadjuvant chemotherapy (CT) in locally advanced breast cancer (LABC).
    Alkhatib, F
    Alawadi, S
    Grohn, P
    Motawy, M
    Fayaz, S
    Patel, J
    Attia, N
    Trad, D
    Delvadia, M
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 21 - 22
  • [3] Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer
    E. Espinosa
    S. Morales
    P. Borrega
    A. Casas
    C. Madroñal
    I. Machengs
    J. A. Illarramendi
    J. Lizón
    J. A. Moreno
    J. Belón
    J. Janáriz
    M. de la Puente
    T. Checa
    J. R. Mel
    M. González Barón
    [J]. Cancer Chemotherapy and Pharmacology, 2004, 54 : 546 - 552
  • [4] Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer
    Espinosa, E
    Morales, S
    Borrega, P
    Casas, A
    Madroñal, C
    Machengs, I
    Illarramendi, J
    Lizón, J
    Moreno, J
    Belón, J
    Janáriz, J
    de la Puente, M
    Checa, T
    Mel, JR
    Barón, MG
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (06) : 546 - 552
  • [5] Epirubicin and Docetaxel as Primary Chemotherapy in Locally Advanced Breast Cancer
    Conti, F.
    Corsetti, S.
    Viola, G.
    Sperduti, I.
    Carpano, S.
    Pizzuti, L.
    Foggi, P.
    Perri, P.
    Anza, M.
    Toglia, G.
    Lopez, M.
    [J]. ONCOLOGY, 2009, 77 : 139 - 140
  • [6] Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer
    Won, Hye Sung
    Kim, Yong Seok
    Kim, Jeong Soo
    Chang, Eun Deok
    Na, Sae Jung
    Whang, In Yong
    Lee, Dong Soo
    [J]. KOREAN JOURNAL OF INTERNAL MEDICINE, 2020, 35 (06): : 1489 - 1496
  • [7] Neoadjuvant chemotherapy in locally-advanced breast cancer:: A preliminary report
    Baltali, E
    Firat, D
    Öncel, N
    Onat, DA
    Atahan, IL
    Büyükünal, E
    Çelik, I
    Aktan, G
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 : S35 - S35
  • [8] Efficacy of neoadjuvant weekly docetaxel in locally advanced or inflammatory breast cancer
    Basarakodu, K. R.
    Linebaugh, J. A.
    Barrett, B. K.
    Perry, M. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma
    Chen, SC
    Chang, HK
    Lin, YC
    Cheung, YC
    Tsai, CS
    Leung, WM
    Hsueh, S
    Chen, MF
    [J]. ONKOLOGIE, 2005, 28 (6-7): : 339 - 344
  • [10] Neoadjuvant chemotherapy with Vinorelbine and Epirubicin in locally advanced breast cancer (LABC).
    Puerto, VL
    Cardenas, J
    Lara, F
    Goana, R
    Silva, A
    Barroso, N
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 299 - 299
12345